Search research articles
Contact Us
Filters
Showing results (91-100 of 145) with videos related to
Page
of 15
Sort By:
Annales Pharmaceutiques Francaises
|
October 10, 2025
The evolving role of Hospital Oncology Pharmacists (HOPs) in assessing therapeutic innovations and managing toxicities in cancer care
Florence Ranchon, Florian Slimano, Maha Ayyoub, et al.
Drugs in R&D
|
September 25, 2021
Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy
Pauline Vaflard, Xavier Paoletti, Vincent Servois, et al.
Pharmaceutical Statistics
|
March 15, 2019
Response to comments on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharm Stat 17(5):593-606, Sep/Oct 2018., DOI: https://doi.org/10.1002/pst.1873
Thomas Jaki, Allan Gordon, Pamela Forster, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 15, 2014
Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey
Xavier Paoletti, Christophe Le Tourneau, Jaap Verweij, et al.
Nature Reviews. Clinical Oncology
|
May 17, 2017
Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective
Lucas Moreno, Andrew D J Pearson, Xavier Paoletti, et al.
Pediatric Blood & Cancer
|
August 25, 2016
Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials
Lucas Moreno, Herve Rubie, Amalia Varo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 23, 2021
Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium
Claudia Pasqualini, Jonathan Rubino, Caroline Brard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 6, 2012
Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials
Carine A Bellera, Marina Pulido, Sophie Gourgou, et al.
Breast Cancer Research : BCR
|
May 29, 2020
COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area
Perrine Vuagnat, Maxime Frelaut, Toulsie Ramtohul, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 2, 2020
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)
Philipp Harter, Patricia Pautier, Els Van Nieuwenhuysen, et al.
Page
of 15
Search research articles
Search
Showing results (91-100 of 145) with videos related to
Sort By:
Page
of 15
Annales Pharmaceutiques Francaises
|
October 10, 2025
The evolving role of Hospital Oncology Pharmacists (HOPs) in assessing therapeutic innovations and managing toxicities in cancer care
Florence Ranchon, Florian Slimano, Maha Ayyoub, et al.
Drugs in R&D
|
September 25, 2021
Dissociated Responses in Patients with Metastatic Solid Tumors Treated with Immunotherapy
Pauline Vaflard, Xavier Paoletti, Vincent Servois, et al.
Pharmaceutical Statistics
|
March 15, 2019
Response to comments on Jaki et al., A proposal for a new PhD level curriculum on quantitative methods for drug development. Pharm Stat 17(5):593-606, Sep/Oct 2018., DOI: https://doi.org/10.1002/pst.1873
Thomas Jaki, Allan Gordon, Pamela Forster, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 15, 2014
Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey
Xavier Paoletti, Christophe Le Tourneau, Jaap Verweij, et al.
Nature Reviews. Clinical Oncology
|
May 17, 2017
Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective
Lucas Moreno, Andrew D J Pearson, Xavier Paoletti, et al.
Pediatric Blood & Cancer
|
August 25, 2016
Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials
Lucas Moreno, Herve Rubie, Amalia Varo, et al.
European Journal of Cancer (Oxford, England : 1990)
|
April 23, 2021
Phase II and biomarker study of programmed cell death protein 1 inhibitor nivolumab and metronomic cyclophosphamide in paediatric relapsed/refractory solid tumours: Arm G of AcSé-ESMART, a trial of the European Innovative Therapies for Children With Cancer Consortium
Claudia Pasqualini, Jonathan Rubino, Caroline Brard, et al.
European Journal of Cancer (Oxford, England : 1990)
|
November 6, 2012
Protocol of the Definition for the Assessment of Time-to-event Endpoints in CANcer trials (DATECAN) project: formal consensus method for the development of guidelines for standardised time-to-event endpoints' definitions in cancer clinical trials
Carine A Bellera, Marina Pulido, Sophie Gourgou, et al.
Breast Cancer Research : BCR
|
May 29, 2020
COVID-19 in breast cancer patients: a cohort at the Institut Curie hospitals in the Paris area
Perrine Vuagnat, Maxime Frelaut, Toulsie Ramtohul, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
July 2, 2020
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34)
Philipp Harter, Patricia Pautier, Els Van Nieuwenhuysen, et al.
Page
of 15